Your browser doesn't support javascript.
loading
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials.
Yang, Min; Zhang, Wenhao; Yu, Kang; Wang, Peng; Jiang, Hua; Chen, Linjun; Meng, Haitao; Weng, Yiqin; Tao, Rong; Huang, Xin; Xing, Chongyun; Wang, Huamao; Wan, Jiangbo; Wang, Shasha; Dai, Lihui; Hendrix, Amanda Y; Xiao, Jun; Wang, Wei; Ma, Hong; Hao, Siguo; Jin, Jie; Li, Zonghai; Jiang, Songfu.
Afiliação
  • Yang M; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou. jiej0503@163.com.
  • Zhang W; Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai. haosiguo@xinhuamed.com.cn
  • Yu K; Department of Hematology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou. jiej0503@163.com.
  • Wang P; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
  • Jiang H; CARsgen Therapeutics Co. Ltd, Shanghai.
  • Chen L; Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai. haosiguo@xinhuamed.com.cn
  • Meng H; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou. jiej0503@163.com.
  • Weng Y; Department of Hematology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou. jiej0503@163.com.
  • Tao R; Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai. haosiguo@xinhuamed.com.cn
  • Huang X; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou. jiej0503@163.com.
  • Xing C; Department of Hematology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou. jiej0503@163.com.
  • Wang H; CARsgen Therapeutics Co. Ltd, Shanghai.
  • Wan J; Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai. haosiguo@xinhuamed.com.cn
  • Wang S; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou. jiej0503@163.com.
  • Dai L; Department of Hematology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou. jiej0503@163.com.
  • Hendrix AY; CARsgen Therapeutics Corp., Houston, TX.
  • Xiao J; CARsgen Therapeutics Co. Ltd, Shanghai.
  • Wang W; CARsgen Therapeutics Co. Ltd, Shanghai.
  • Ma H; CARsgen Therapeutics Corp., Houston, TX.
  • Hao S; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zonghaili@shsmu.edu.cn.
  • Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou. jiej0503@163.com.
  • Li Z; CARsgen Therapeutics Co. Ltd, Shanghai.
  • Jiang S; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zonghaili@shsmu.edu.cn.
Haematologica ; 107(8): 1960-1965, 2022 08 01.
Article em En | MEDLINE | ID: mdl-35443566
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Plasmócitos / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Plasmócitos / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2022 Tipo de documento: Article